Recent Company News

• 03:11 AM ET Mar 31, 2026
  

  Teijin guides FY net income attributable (¥95.00-85.00B) vs prior guidance (¥10.00B) and FactSet (¥8.80B) [5 est, (¥12)-(5B)] (¥1632.0000, 0)

• 08:34 AM ET Mar 17, 2026
  

  Ascendis Pharma announces positive Week 52 topline results from New InsiGHTS Phase II trial ($231.03, 0.00)

• 08:04 AM ET Mar 16, 2026
  

  New two-year data from pivotal approach trial showing durable benefits of TransCon CNP (navepegritide) in children with achondroplasia shared at ACMG 2026 ($225.98, 0.00)

• 10:21 PM ET Mar 02, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (149 total)

• 04:43 PM ET Feb 27, 2026
  

  FDA approves Ascendis Pharma's TransCon CNP NDA for achondroplasia in children ($233.50, 0.00)

• 09:43 PM ET Feb 26, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (133 total)

• 09:07 PM ET Feb 16, 2026
  

  Teijin Pharma, Aska Pharmaceutical jointly develop novel small-molecule drug candidates for gynecological diseases (¥1691.5000, +17)

• 10:50 PM ET Feb 11, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (205 total)

• 10:07 PM ET Feb 09, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (450 total)

• 10:07 PM ET Feb 08, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (571 total)